Objective: To evaluate exercise capacity in children and adolescents with post-infectious bronchiolitis obliterans.

Data source: This is a systematic review based on data from PubMed, Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS), Scientific Electronic Library Online (SciELO), and Physiotherapy Evidence Database (PEDro). We used the following search strategy: “Exercise capacity OR Exercise Test OR Physical fitness OR Functional capacity OR Six-minute walk test OR Shuttle walk test OR Cardiopulmonary exercise test AND Bronchiolitis obliterans.” We selected studies that evaluated exercise capacity through maximal/submaximal testing in children and adolescents with post-infectious bronchiolitis obliterans, and no other associated disease. We searched articles in English, Portuguese, and Spanish, without restrictions regarding the period of publication. The methodological quality was assessed by the Agency for Healthcare Research and Quality (AHRQ) protocol.

Data synthesis: Out of the 81 articles found, only 4 were included in this review. The studies totaled 135 participants (121 with post-infectious bronchiolitis obliterans and 14 healthy), with sample sizes between 14 and 58 subjects. All patients underwent spirometry to evaluate pulmonary function, indicating an obstructive ventilatory pattern. Among them, 3/4 had their physical performance assessed by the six-minute walk test and 2/4 by the cardiopulmonary exercise testing. These test results were compared to those of a control group (1/4) and presented as percentage of predicted and/or in meters (3/4). Lastly, 3/4 of the studies showed reduced exercise capacity in this population. The studies included were classified as having high methodological quality.

ABSTRACT

Capacidade de exercício em crianças e adolescentes com bronquiolite obliterante pós-infecciosa: uma revisão sistemática

Camila Menna Barros Rodriguesa, Daniele Schiweb, Natália Evangelista de Camposb, Fabiana Niederauera, João Paulo Heinzmann-Filhob,*

REVIEW ARTICLE

Corresponding author. E-mail: joao.heinzmann@pucrs.br (J.P. Heinzmann Filho).

*Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.
©Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Received on November 28, 2017; approved on March 25, 2018; available online on February 28, 2019.
**INTRODUCTION**

Post-infectious bronchiolitis obliterans (PIBO) is an inflammatory disease of the distal airways, resulting from damage to the lower respiratory tract. Inflammation and fibrosis of terminal bronchioles cause narrowing and/or complete obliteration of the airway lumen, leading to chronic airflow obstruction.1-7 These anatomofunctional changes can result in progressive loss of strength/endurance of ventilatory muscles, directly contributing to the reduction in activities of daily living (ADLs), with a consequent negative impact on exercise tolerance.8

Reduction in exercise tolerance for individuals with respiratory diseases has a significant association with quality of life, hospitalizations, medicines, survival time, and clinical prognosis.8-10 In this regard, field/laboratory functional tests are considered essential components in the routine of clinical evaluation of patients, due to their clear and objective way of measuring functional capacity and the reasons for exercise intolerance, and for prescription of an appropriate physical training program.11,12 Among these tests, we can mention the cardiopulmonary exercise testing (CPET) and the six-minute walk test (6MWT).13,14

Current data suggest that results of exercise tests could be more sensitive in detecting early involvement in respiratory diseases when compared to the forced expiratory volume in one second (FEV1), measured by spirometry. This fact is due to physical performance tests evaluating the communication of ventilatory, cardiac, and metabolic systems in an integrated and dynamic way, while spirometry is just a static pulmonary measurement.3,15-18

Although CPET and 6MWT results are widely known in some chronic lung diseases in children, including cystic fibrosis and asthma,19-21 these findings are more restricted in PIBO.22,23 To date, few studies have evaluated functional capacity in patients with PIBO, especially in the pediatric population.21,24 In addition, we found no systematic and critical review aimed at evaluating exercise capacity with different functional tests in children and adolescents with PIBO, justifying the development of this study. A better understanding and knowledge about the topic can alert the professionals involved in the care of these patients to the need of designing effective strategic measures to fight exercise intolerance.

**METHOD**

This is a systematic review conducted by searching databases from PubMed, Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS), Scientific Electronic Library Online (SciELO), and Physiotherapy Evidence Database (PEDro). We selected observational studies in English, Portuguese, and Spanish, without filters regarding age and year of publication of articles. The selection of studies occurred in June 2017.

The search adopted to choose the articles was based on eight keywords associated with Boolean operators. We used the following strategy: “Exercise capacity OR Exercise Test OR Physical fitness OR Functional capacity OR Six-minute walk test OR Shuttle walk test OR Cardiopulmonary exercise test AND Bronchiolitis obliterans”. These terms should appear, at least, in the heading, abstract, or keywords.

We included studies that evaluated exercise capacity using maximal and/or submaximal testing in children and adolescents with PIBO and no other associated disease. Exercise capacity was considered preserved when the results of the distance covered or maximal oxygen uptake were ≥80% of predicted, or when data were compared to a control group. Also, in the absence of previous criteria, the subjects were classified as having preserved physical capacity when they covered a distance ≥476 m on 6MWT.21 In contrast, we excluded review studies, case reports, articles that did not assess exercise capacity, and those that evaluated only adults. We also excluded studies involving individuals with other chronic diseases, neurological disorders, orthopedic problems, and/or cognitive limitations.

Later, we identified the terms in the headings, and read the abstracts of the selected articles to assess whether they fit the eligibility criteria. Studies that presented the predetermined...
criteria had the full text purchased for data extraction and analysis. Two raters searched and analyzed the articles independently, and a third resolved disagreements consensually.

We registered the following characteristics of the studies: name of the first author/year of publication, country (origin) of data collection, groups assessed (PIBO and healthy), age group, sample size, data on pulmonary function (spirometry), exercise testing performed, and main results found (reduced, preserved, or improved physical capacity).

We used a scale suitable for observational studies from the Agency for Health Care Research and Quality (AHRQ). This instrument evaluates nine items related to the study question, methodological aspects, consistency of results, discussion, and sponsorship. The final sum of each item evaluated is 100 points, with studies classified as having low (<50 points), moderate (50–66 points), and high (>66 points) methodological quality.

RESULTS
Out of 81 articles, 75 were found in PubMed, three in LILACS, three in SciELO, and none in PEDro. We excluded five studies for appearing in more than one of the databases used, and 72 for not meeting the eligibility criteria of this review. Thus, we included only four studies that evaluated exercise capacity in children and adolescents with PIBO. Figure 1 shows the flowchart related to the total number of articles found.

The selected articles totaled a sample of 135 participants (121 with PIBO and 14 healthy). The sample size of the studies varied between 14 and 58 subjects, with ages ranging from 8 to 23 years (Table 1). Two studies (50.0%) evaluated exercise capacity with 6MWT; one (25.0%) with CPET; and one (25.0%) with both tests. Only one study of this review (25.0%) used a control group.

Data on pulmonary function (% of predicted) included FEV₁, forced vital capacity (FVC), the Tiffeneau index (FEV₁/FVC),...
FVC), and forced expiratory flow in 25 and 75% of FVC (FEF_{25-75}), indicating moderate/severe pulmonary involvement. The parameters evaluated with exercise testing included the distance covered (meters and % of predicted) and maximal oxygen uptake (VO_{2max}) (% of predicted). Approximately 75.0% of the studies demonstrated that children and adolescents with PIBO had reduced exercise capacity. Table 2 presents this information in detail.

The mean score of methodological quality of the selected articles was 77.25 points, ranging from 73 to 82 (Table 3). All studies (100%) reached a score compatible with high methodological quality, according to the AHRQ scale. Factors that decreased the quality score concerned some items related to the population evaluated, comparability of studies (inclusion/exclusion criteria), result measurements (blinding), and statistical analysis (sample calculation).

**DISCUSSION**

In this review, we identified four studies\textsuperscript{11,22-24} with high methodological quality that evaluated exercise capacity in children and adolescents with PIBO. Among them, 75.0% showed reduced functional capacity, measured both by laboratory (maximal) and field (submaximal) tests. In patients with chronic lung disease, the measurement of physical fitness is considered part of the multidimensional assessment, since it objectively evaluates

**Table 1** Identification and characteristics of the studies included in this review.

| First author & year | Country (origin) | Groups assessed | Age group (years) | Sample size |
|---------------------|------------------|-----------------|-------------------|------------|
| Frohlich et al. (2014)\textsuperscript{22} | Brazil | Healthy | 10–23 | 14 |
| | | PIBO | 10–23 | 16 |
| Zenteno et al. (2009)\textsuperscript{23} | Chile | PIBO | 8–14 | 27 |
| Mattiello et al. (2008)\textsuperscript{11} | Brazil | PIBO | 8–16 | 20 |
| Gerbase et al. (2008)\textsuperscript{24} | Switzerland | PIBO | 5.6±2.9,\textsuperscript{*} | 58 |

PIBO: post-infectious bronchiolitis obliterans; *data presented in mean and standard deviation.

**Table 2** Characteristics and main results of the studies included in this review.

| First author & year | Groups assessed | Pulmonary function (% of predicted) | Exercise testing used | Results of the exercise testing (% of predicted) | Conclusion of the exercise capacity |
|---------------------|-----------------|-----------------------------------|----------------------|-----------------------------------------------|----------------------------------|
| Frohlich et al. (2014)\textsuperscript{22} | Healthy | FEV\textsubscript{1}: 112±15 FVC: 112±16 FEV\textsubscript{1}/FVC: 99±03 | CPET | VO_{2max}: 101±17 | Reduced exercise capacity compared to healthy individuals (p-value<0.05) |
| | PIBO | FEV\textsubscript{1}: 60±30 FVC: 74±22 FEV\textsubscript{1}/FVC: 78±21 | | VO_{2max}: 84±15 | |
| Zenteno et al. (2009)\textsuperscript{23} | PIBO | FVC: 85.4±15 FEV\textsubscript{1}: 58.3±23 FEV\textsubscript{1}/FVC: 59.3±32 FEF\textsubscript{25-75}: 31.7±25 | 6MWT | Distance covered: 598±71\textsuperscript{*} | Preserved exercise capacity (>476 m) |
| Mattiello et al. (2008)\textsuperscript{11} | PIBO | FEV\textsubscript{1}: 57.7±17.9 FVC: 66.8±17.3 FEV\textsubscript{1}/FVC: 57.9±12.5 FEF\textsubscript{25-75}: 20.4±12.6 | 6MWT | Distance covered: 77±15.7 VO_{2max}: 77.5±37.5 | Reduced exercise capacity (<80% of predicted) |
| Gerbase et al. (2008)\textsuperscript{24} | PIBO | FEV\textsubscript{1}: 73.9±25.1 | 6MWT | Distance covered: 30.4 (4.5–8.1)* | Reduced exercise capacity (<80% of predicted) |

%: percentage; PIBO: post-infectious bronchiolitis obliterans; FEV\textsubscript{1}: forced expiratory volume in 1 second; FVC: forced vital capacity; FEV\textsubscript{1}/FVC: Tiffeneau index; FEF\textsubscript{25-75}: forced expiratory flow; CPET: cardiopulmonary exercise testing; 6MWT: six-minute walk test; VO_{2max}: maximal oxygen uptake; *data expressed in median and variation; \*data presented in meters.
the interaction among the cardiac, ventilatory, muscular, and metabolic systems.26

The main reasons for exercise intolerance in patients with lung disease include isolated or associated factors, such as the enhancement of symptoms (fatigue in lower limbs and dyspnea), development of dynamic hyperinflation, peripheral muscle dysfunction, abnormalities in oxygen transport, and progressive physical deconditioning related to inactivity.8,12 Furthermore, the lack of ventilatory reserve observed by the high ventilation reached in CPET (almost all of the maximal voluntary ventilation predicted) also seems to be related to the low physical performance of these patients, a fact attributed to the obstructive ventilatory pattern in these subjects, which directly limits the airflow.17

In the present review, three studies used 6MWT (two exclusively and one with CPET) to measure exercise capacity in patients with PIBO.11,23,24 Among them, two showed reduced functional capacity,11,24 while the other23 presented values within the cohort point (>476 m), considered the lower normal limit.21 Clinically, 6MWT relates to ADLs and investigates the need for supplemental oxygen therapy,27 in addition to being more indicated for patients with lung diseases in more advanced stages, due to its low sensitivity in early stages.27,28 This fact can be observed in this review, considering that 6MWT detected reduced exercise capacity in subjects with moderate/severe pulmonary involvement.

Only the study by Zenteno et al.23 was classified as having preserved physical capacity, based on our methodological criteria. However, this interpretation might have been affected by the lack of standardization of results of distance covered by a reference equation. Nonetheless, we used cohort points described in the literature to aid in this categorization.21 This cohort point was chosen for being an intermediate value (between 400 and 577.5 m) of the distance covered in 6MWT, used in studies that evaluated best/worst clinical prognosis in patients with lung diseases.9,21,28 Based on the results of this review, 6MWT can be the first choice to assess physical performance in pediatric patients with PIBO who present moderate/severe pulmonary involvement, considering its good detection power for impaired physical performance in these samples.

All studies that assessed physical fitness with CPET (2/4 of the articles: 50 subjects out of 135 – PIBO and control group – and 36 out of 121 – only PIBO) demonstrated exercise intolerance in patients with PIBO. CPET is considered the gold-standard method to investigate physical fitness, obtaining as clinical variables VO2max; maximal ventilation; respiratory equivalent for both oxygen and carbon dioxide; and ventilatory and cardiac reserves.29 In chronic respiratory diseases, the main outcome used is VO2max, a variable adopted in our review to interpret data.16,29 VO2max has a good relationship with other clinical markers and is often used as an indicator of life expectancy in many lung diseases. Among its associations, we can mention the correlation with body mass index (BMI), clinical severity scores, and pulmonary function.10,16,29 Although the studies included in this review have used different ergometers (treadmill and cycle ergometer), both adopted incremental loading protocols, either by speed/slope or load (power).11,22-24 These protocols are the most recommended to measure physical fitness, considering that they lead the subjects to progressive cardiovascular stress, nearly exhausting them.16

Table 3 Assessment of the methodological quality of the studies included in this systematic review.

| Criteria evaluated* | Reference score | Frohlich et al. (2014)22 | Zenteno et al. (2009)23 | Mattiello et al. (2008)11 | Gerbase et al. (2008)24 |
|---------------------|-----------------|-------------------------|------------------------|--------------------------|-------------------------|
| Study question      | 2               | 2                       | 2                      | 2                        | 2                       |
| Study population    | 8               | 5                       | 5                      | 8                        | 5                       |
| Comparability of individuals for observational studies | 22 | 19 | 19 | 19 | 17 |
| Exposure or intervention | 11 | 11 | 11 | 11 | 11 |
| Result measurements | 20              | 15                      | 15                     | 15                       | 15                      |
| Statistical analysis| 19              | 12                      | 12                     | 14                       | 12                      |
| Results             | 8               | 8                       | 8                      | 8                        | 8                       |
| Discussion          | 5               | 5                       | 5                      | 5                        | 3                       |
| Funding and sponsorship | 5       | 0                       | 0                      | 0                        | 0                       |
| Total score         | 100             | 77                      | 77                     | 82                       | 73                      |

*Some items assessed in this scale did not directly apply to the design of the studies.
All studies assessed pulmonary function in children and adolescents with PIBO, investigating the FEV₁, FVC, and FEV₁/FVC ratio. The typical ventilatory pattern of the disease is a severe ventilatory obstruction, which often does not respond to the treatments administered. The patient usually presents wheezing, tachypnea, dyspnea, and persistent cough for weeks or months after the initial infection. After the initial attack, the disease can persist for years, with exacerbations by viral infections, resulting in atelectasis and pneumonia. The present study identified a moderate/severe obstructive pattern, based on spirometry results, which corroborates the description of the disease and other previous studies. An important fact found in patients with chronic obstructive pulmonary disease was that 30% of the variability in exercise performance was attributed to airway obstruction observed with FEV₁. These findings lead to the importance of the multi-professional team in thoroughly evaluating these subjects, taking into account that other factors, such as the usual level of physical activity, physical conditioning, and muscle capacity (peripheral and respiratory), can also have an important role in their aerobic fitness.

The studies included in this review seem to have some limitations, such as small sample size, variation in age group (5 to 23 years), lack of standardization of 6MWT results, and only one study having a control group. However, we believe that such restrictions did not influence the research question investigated due to the high methodological quality reached by the studies and to most of them presenting outcomes of exercise capacity after standardization of data by reference equations.

In sum, the findings of this review showed reduced exercise capacity in children and adolescents with PIBO in most of the studies included. These results demonstrated the impact of this disease on the pediatric age group, considering that poor results in exercise tolerance are associated with worse outcomes regarding hospitalizations, the use of antibiotic therapy, and the reduced survival time of patients with respiratory diseases. Such fact should alert the professionals involved in this type of care, aiming to include them in pulmonary rehabilitation programs to decrease the impact of this disease, and improve the quality of life of these patients.

Funding
This study did not receive funding.

Conflict of interests
The authors declare no conflict of interests.

REFERENCES

1. Vieira GD, Yamagishi AV, Vieira NN, Fogaça RM, Alves TC, Amaral GM, et al. Complication of post-infectious bronchiolitis obliterans (Swyer-James syndrome). Rev Assoc Med Bras. 2015;61:404-6.

2. Hochhegger B, Baldisserotto M. Chest computed tomography in bronchiolitis obliterans after bone marrow transplantation. Radiol Bras. 2017;50:IX.

3. Champs NS, Lasmar LM, Camargos PA, Marguet C, Fischer GB, Mocelin HT. Post-infectious bronchiolitis obliterans in children. J Pediatr (Rio J). 2011;87:187-98.

4. Lino CA, Batista AK, Soares MA, Freitas AE, Gomes LC, Maia Filho JH, et al. Bronchiolitis obliterans: clinical and radiological profile of children followed-up in a reference outpatient clinic. Rev Paul Pediatr. 2013;31:10-6.

5. Calabrese C, Corcione N, Rea G, Stefanelli F, Meoli L, Vatrella A. Impact of long-term treatment with inhaled corticosteroids and bronchodilators on lung function in a patient with post-infectious bronchiolitis obliterans. J Bras Pneumol. 2016;42:228-31.

6. Nascimento FA, Nery J, Riedi CA. Post-infectious bronchiolitis obliterans in children: a review. J Paranaense Ped. 2013;14:37-41.

7. Paludo J, Mocelin HT, Benedetti FJ, Mattiello R, Sarria EE, Mello ED, et al. Energy balance in children and adolescents with post-infectious bronchiolitis obliterans. Rev Nutr. 2012;25:219-28.

8. ERS Task Force, Palange P, Ward S, Carlsen K, Casaburi R, Gallagher C, et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J. 2007;29:185-209.

9. Donadio MV, Heinzmann-Filho JP, Vendrusculo FM, Frasson PX, Marostica PJ. Six-minute walk test results predict risk of hospitalization for youths with cystic fibrosis: a 5-year follow-up study. J Pediatr. 2017;182:204-9.

10. Pérez M, Groeneveld IF, Santana-Sosa E, Fiuza-Luces C, Gonzalez-Saiz L, Villa-Asensi JR, et al. Aerobic fitness is associated with lower risk of hospitalization in children with cystic fibrosis. Pediatr Pulmonol. 2014;49:641-9.

11. Mattiello R, Sarria EE, Stein R, Fischer GB, Mocelin HT, Barreto SS, et al. Functional capacity assessment during exercise in children and adolescents with post-infectious bronchiolitis obliterans. J Pediatr (Rio J). 2008;84:337-43.

12. [No authors listed]. Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. Eur Respir J. 1997;10:2662-89.

13. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS committee on proficiency standards for clinical pulmonary function laboratories. Am J Respir Crit Care Med. 2002;166:111-7.
14. Thompson PD, Arena R, Riebe D, Pescatello LS, American College of Sports Medicine. ACSM’s new preparticipation health screening recommendations from ACSM’s guidelines for exercise testing and prescription. Curr Sports Med Rep. 2013;12:215-7.

15. Heinzmann-Filho JP, Pinto LA, Marostica PJ, Donadio MV. Variation in lung function is associated with worse clinical outcomes in cystic fibrosis. J Bras Pneumol. 2015;41:509-15.

16. Neder JA, Nery LE. Teste de exercício cardiopulmonar. J Bras Pneumol. 2002;28:S166-206.

17. Urquhart DS, Vendrusculo FM. Clinical interpretation of cardiopulmonary exercise testing in cystic fibrosis and implications for exercise counselling. Paediatr Respir Rev. 2017;24:72-8.

18. Hebestreit H, Arets HG, Aurora P, Boas S, Cerny F, Hulzebos EH, et al. Statement on exercise testing in cystic fibrosis. Respiration. 2015;90:332-51.

19. Pereira LF, Mancuzo EV, Rezende CF, Córrea RA. Six-minute walk test and respiratory muscle strength in patients with uncontrolled severe asthma: a pilot study. J Bras Pneumol. 2015;41:211-8.

20. Andrade LB, Silva DA, Salgado TL, Figueroa JN, Lucena-Silva N, Britto MC. Comparison of six-minute walk test in children with moderate/severe asthma with reference values for healthy children. J Pediatr (J Rio). 2014;90:250-7.

21. Martin C, Chapron J, Hubert D, Kanaan R, Honoré I, Paillasue JL, et al. Prognostic value of six minute walk test in cystic fibrosis adults. Respir Med. 2013;107:1881-7.

22. Frohlich LF, Vieira PJ, Teixeira PJ, Silva FA, Ribeiro JP, Berton DC. Exercise capacity in adolescent and adult patients with post infectious bronchiolitis obliterans. Pediatr Pulmonol. 2014;49:911-8.

23. Zenteno D, Popppo H, González R, Pavón D, Vera R, Torres R, et al. Six minute walk test in children with post-infectious bronchiolitis obliterans. Its relation with spirometry. Rev Chil Enferm Respir. 2008;24:15-9.

24. Gerbase MW, Soccal PM, Spiliopoulos A, Nicod LP, Rochat T. Long-term health-related quality of life and walking capacity of lung recipients with and without bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2008;27:898-904.

25. West S, King V, Carey TS, Lohr KN, Mckoy N, Sutton SF, et al. Systems to rate the strength of scientific evidence. Evid Rep Technol Assess (Summ). 2002;47:1-11.

26. Polkey MI, Spruit MA, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med. 2013;187:382-6.

27. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS Statement: guidelines for the Six-Minute Walking Test. Am J Respir Crit Care Med. 2002;166:111-7.

28. Morales-Blahnil JE, Palafax Vidal CD, Rosas Romero MJ, García Castro MM, Londoño Villegas A, Zamboni M. Six-minute walk test: a valuable tool for assessing pulmonary impairment. J Bras Pneumol. 2011;37:110-7.

29. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavié CJ. 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J. 2018;39:1144-61.

30. Hardy KA, Schidlow DV, Zerri N. Obliterative bronchiolitis in children. Chest. 1988;93:460-6.

31. Colom AJ, Maffey AF, Navarra F, Teper A. Pulmonary function in children with post-viral chronic pulmonary disease (PCPD). ATS International Conference 2002; Atlanta, USA: ATS; 2002. p. A159.

32. Cazzato S, Poletti V, Bernardi F, Lorni L, Bertelli L, Colonna S, et al. Airway inflammation and lung function decline in childhood post-infectious bronchiolitis obliterans. Pediatr Pulmonol. 2008;43:381-90.

33. Lama VN, Murray S, Lonigro RJ, Toews GB, Chang A, Lau C, et al. Course of FEV1 after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med. 2007;175:1192-8.

34. Pastré J, Prévotat A, Tardif C, Langlois C, Duhamel A, Wallaert B. Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease. BMC Pulm Med. 2014;14:74.

35. Colom AJ, Teper AM, Vollmer WM, Diette GB. Risk factors for the development of bronchiolitis obliterans in children with bronchiolitis. Thorax. 2006;61:503-6.